Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors

Background: Bladder urothelial cancer (BLCA) treatment using immune checkpoint inhibitors (IMCIs) can result in long-lasting clinical benefits. However, only a fraction of patients respond to such treatment. In this study, we aimed to identify the relationships between immune cell infiltration level...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Shen, Zhan, Yunhong, Chen, Xiaonan, Wu, Bin, Liu, Bitian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834825/
https://www.ncbi.nlm.nih.gov/pubmed/31737562
http://dx.doi.org/10.3389/fonc.2019.01101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834825/
https://www.ncbi.nlm.nih.gov/pubmed/31737562
http://dx.doi.org/10.3389/fonc.2019.01101

Ejemplares similares